Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS



Date/App# patent app List of recent Immunotherapy-related patents
08/20/15
20150232542 
 Human anti-alpha-synuclein antibodies patent thumbnailHuman anti-alpha-synuclein antibodies
Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed.
University Of Zurich


08/13/15
20150224189 
 Silicon dioxide nanoparticles and the use thereof for vaccination patent thumbnailSilicon dioxide nanoparticles and the use thereof for vaccination
The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer.
Merck Patent Gmbh


08/13/15
20150224182 
 Target peptides for immunotherapy and diagnostics patent thumbnailTarget peptides for immunotherapy and diagnostics
A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/mhc complex..
U.va. Licensing & Ventures Group


08/13/15
20150224143 
 Selective and controlled expansion of educated nk cells patent thumbnailSelective and controlled expansion of educated nk cells
The present invention relates generally to immunotherapy. Disclosed herein are methods for obtaining cytolytic differentiated nkg2a−nkg2c+ cells with a given kir specificity and also compositions comprising these cells as well as the use of these cells for therapy.
Inven2 As


08/06/15
20150218216 
 Psf1-derived peptide patent thumbnailPsf1-derived peptide
The purpose of the present invention is to provide a psf1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides: a psf1-derived peptide which can induce a ctl; and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention..
Genestem Co., Ltd.


08/06/15
20150216997 
 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity patent thumbnailDosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


08/06/15
20150216843 
 Inhibition of cxcr4 signaling in cancer immunotherapy patent thumbnailInhibition of cxcr4 signaling in cancer immunotherapy
The inventions describes a method for increasing effector t cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of cxcr4 signaling.. .
Cambridge Enterprise Limited


07/30/15
20150212090 
 Use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer patent thumbnailUse of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer
Methods for predicting cancer recurrence following a bcg immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a bcg therapy and the changes in cytokine levels are used to determine the risk of cancer lapse.
Board Of Regents, The University Of Texas System


07/30/15
20150210759 
 Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof patent thumbnailHuman islet amyloid polypeptide (hiapp) specific antibodies and uses thereof
Provided are novel human islet amyloid polypeptide, also known as amylin and iapp and proiapp respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for iapp and/or proiapp are also disclosed.
Neurimmune Holding Ag


07/23/15
20150203817 
 Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells patent thumbnailUse of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
A method of expanding tcralpha deficient t-cells by expressing ptalpha or functional variants thereof into said cells, thereby restoring a functional cd3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary t-cells from donors.
Cellectis


07/23/15
20150203562 

Compounds and methods for modulating pharmacokinetics


Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (hb). Compounds may be administered to tissues including skin.
The Brigham And Women's Hospital, Inc.


07/23/15
20150202320 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/23/15
20150202319 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196774 

Laser immunotherapy


A method of immunotherapy of a mammal or a laser device therefor, includes the step of treating one or more immune privileged cells, tissue or organs of said mammal with a laser to reduce or eliminate the immune privilege status of said one or more cells, tissues and/or organs to thereby elicit an immune response that is beneficial to the mammal. The method of immunotherapy avoids or minimizes lasting damage to the treated cells, tissues and/or organs.
Ellex Medical Pty Ltd.


07/16/15
20150196666 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196665 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196664 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196662 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196661 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196654 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196653 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196626 

Modulation of yeast-based immunotherapy products and responses


Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions..
The Regents Of The University Of Colorado, A Body Corporate


07/09/15
20150191525 

Ox40l fusion protein for the immunotherapy of tumors of veterinary animals


Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine ox40l extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine ox40l extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof..

07/09/15
20150191516 

Ly6k epitope peptides for th1 cells and vaccines containing the same


Isolated ly6k-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190490 

Cdca1 epitope peptides for th1 cells and vaccines containing the same


Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190489 

Kif20a epitope peptides for th1 cells and vaccines containing the same


Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science. Inc.


07/09/15
20150190386 

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl) piperidine-2,6-dione in combination with second active agents


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


07/09/15
20150190380 

Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders


Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of sns-595.
Sunesis Pharmaceuticals, Inc.


07/02/15
20150184130 

Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer


Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer..
Sotio A.s.


06/25/15
20150174268 

Compounds for targeted immunotherapy


Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula tm-ln-am, wherein tm is a targeting moiety, am is an activating moiety that is capable of activating a human dendritic cell, nk cell, or tumor cell, or a combination thereof, ln is a linker, and n is an integer selected from 0 and 1..
Shanghai Birdie Biotech, Inc.


06/25/15
20150173406 

Hypoallergenic food-grade protein matrices and uses thereof


This invention relates generally to the discovery of improved food-grade protein matrices with reduced allergeiiicity and uses thereof including immunotherapy.. .
The United States Of America, As Represented By The Secretary Of Agriculture


06/18/15
20150170776 

Method and the production of lead 212 for medical use


The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution a1, characterised in that the lead (212) contained in the aqueous solution a1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column.
Areva Med Sas


06/18/15
20150165075 

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy


Described herein are compositions and methods of use of radionuclide-antibody conjugates (for rait) and drug-antibody conjugates (adc). The combination of rait and adc was more efficacious than either rait alone, adc alone, or the sum of effects of rait and adc.
Immunomedics, Inc.


06/18/15
20150165025 

Methods for treating cancer using anti-pd-1 antibodies


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.


06/18/15
20150165011 

Dna vaccine for use in pancreatic cancer patients


The present invention relates to an attenuated mutant strain of salmonella comprising a recombinant dna molecule encoding a vegf receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of salmonella in cancer immunotherapy..
Vaximm Ag


06/18/15
20150164940 

Liquid medicine having carbon dioxide dissolved therein and therapeutic method using same


A liquid medicine of the present invention comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection, and a method of treatment of the present invention using a liquid medicine comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection can reduce or eliminate tumors with few side effects. When the liquid medicine of the present invention comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection, and the method of treatment of the present invention using a liquid medicine comprising liquid having carbon dioxide dissolved therein, said liquid being administered by using means of liquid injection are used in combination with surgical therapy, chemotherapy, radiotherapy, or immunotherapy of tumors, effects can be enhanced or side effects can be reduced compared with monotherapy or multidisciplinary therapy thereof..
Co2be Medical Engineering K.k.


06/11/15
20150157716 

Methods of identifying and treating poor-prognosis cancers


The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular.
The Trustees Of Princeton University


06/11/15
20150157710 

Dual ox40 agonist/il-2 cancer therapy methods


Ox40 is a potent immune stimulating target. Provided herein is a method of treating cancer, which includes administering to a subject in need of treatment an ox40 agonist and a common gamma chain (yc) cytokine or an active fragment, variant, analog, or derivative thereof.
Providence Health & Services-oregon D/b/a Providence Portland Medical Center


06/04/15
20150152154 

Tumor vaccination involving a humoral immune response against self-proteins


The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag


06/04/15
20150150821 

Vault immunotherapy


The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.. .
The Regents Of The University Of California


05/28/15
20150147347 

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


05/28/15
20150147334 

Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins


The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease..
New York University


05/21/15
20150140039 

Immunological markers for adjuvant therapy in melanoma


The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more snps in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example.
John Wayne Cancer Institute


05/21/15
20150140017 

Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer


The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.. .
Yale University


05/21/15
20150139943 

Chimeric receptors and uses thereof in immune therapy


Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the fc portion of an immunoglobulin molecule (ig) (e.g., an extracellular ligand-binding domain of f158 fcgr3a or v158 fcgr3a variant); a transmembrane domain (e.g., a transmembrane domain of cd8α); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1bb); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (itam) (e.g., a cytoplasmic signaling domain of cd3ζ). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors.
St. Jude Children's Research Hospital


05/14/15
20150132369 

Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof


A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..

05/07/15
20150126459 

Plant profilin polypeptides for use in non-specific allergy immunotherapy


The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. Grass or tree pollen) by bystander suppression with a plant profilin (e.g.
Alk-abello A/s


05/07/15
20150125956 

Composition for maturing dendritic cells, and preparing antigen-specific dendritic cells using same


The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, interleukin-1β (il-1β), interleukin-6 (il-6), tumor necrosis factor-α (tnf-α), interferon-γ (ifn-γ), prostaglandin e2 (pge2), picibanil (ok432) and/or poly ic. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy..
Jw Creagene Inc.


05/07/15
20150125536 

Methods and compositions for sustained immunotherapy


This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership


05/07/15
20150125478 

Novel immunotherapy against several tumors including neuronal and brain tumors


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


05/07/15
20150125477 

Personalized immunotherapy against several neuronal and brain tumors


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


05/07/15
20150125466 

Methods related to cancer treatment


The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“mmp-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of mmp-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher mmp-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy.

05/07/15
20150125463 

Cancer immunotherapy by disrupting pd-1/pd-l1 signaling


The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an ab that inhibits signaling from the pd-1/pd-l1 signaling pathway, or a combination of such ab and an anti-ctla-4 ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express pd-l1 on the cell surface exceeds a predetermined threshold level, and administering an anti-pd-1 ab to the selected subject.
Bristol- Myers Squibb Company


05/07/15
20150125451 

Compositions and methods for beta-glucan immunotherapy


This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy.
Biothera, Inc.


04/30/15
20150118222 

Treatment using bruton's tyrosine kinase inhibitors and immunotherapy


Combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor..
Pharmacyclics, Inc.


04/30/15
20150118181 

Concurrent chemotherapy and immunotherapy


The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (gbm) patients of this agent in order to treat with immunotherapy is controversial.
Duke University


04/23/15
20150110820 

Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy


The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of cpavkrdvdlflt (seq id no: 1) as well as its combinations with other peptides for immunosuppressive purposes.. .
Circassia Limited


04/23/15
20150110797 

Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies


Isolated peptides from the protein emmprin (cd147/basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders..

04/23/15
20150110761 

Expansion of alloantigen-reactive regulatory t cells


The present disclosure relates generally to the manufacture of regulatory t cells (tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive tregs ex vivo.
The Regents Of The University Of California


04/16/15
20150105325 

Recombinant alpha-fetoprotein and compositions thereof


Disclosed are pharmaceutical and synergistic compositions comprising human recombination alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.. .

04/16/15
20150104481 

Water extract of antrodia camphorata for immunostimulatory effect and preparation method thereof


A preparation method for a water extract of the fruiting body of antrodia camphorata (acw) is provided. The method includes steps of: (a) providing the fruiting body; and (b) boiling the fruiting body in water to obtain the water extract.
Kaohsiung Medical University


04/09/15
20150098958 

Influenza nucleoprotein vaccines


The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from influenza strain a, b or c, and a variant of a c4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease..
Imaxio


04/02/15
20150094336 

Methods for treating gliomas with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


04/02/15
20150094335 

Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


03/26/15
20150086612 

Rna formulation for immunotherapy


The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering rna to antigen presenting cells such as dendrite cells (dcs) in the spleen after systemic administration.
Biontech Ag


03/19/15
20150079027 

Antitumor protocol


Improved protocols that enhance the effect of immunotherapy against tumors are described. The protocol involves enhancing the immune response to an antitumor vaccine by maximizing the ability of t cells induced by the vaccine to extravasate into the tumor and also to modulate the effect of tregs so that the effectiveness of the vaccine is not undermined.
Dendritherapeutics, Inc.


03/12/15
20150071967 

Tolerisation-inducing composition


The present invention relates to a composition comprising a tolerogenic peptide and a gsk-3 inhibitor and uses thereof. The invention also relates to the use of a gsk-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines.
University Of Bristol


03/12/15
20150071873 

Cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria


A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a mycobacterium bovis bacillus calmette-guerin (bcg), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of the first composition to a cancer patient before local administration of the second composition at tumor site. A method in vitro for monitoring cancer treatment by immunotherapy with bcg, antigenically related non-pathogenic mycobacteria, or immunogenic component(s) thereof, comprising assaying bcg-specific immune response in a patient..
Universitatsspital Basel


03/12/15
20150071853 

Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof


The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal.
Immune Pharmaceuticals Ltd.


03/05/15
20150065584 

Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis


The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent.
Amderma Pharmaceuticals, Llc


03/05/15
20150064240 

Muc1 based glycolipopeptide vaccine with adjuvant


Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.. .
Oncothyreon Inc.


03/05/15
20150064239 

Methods for identifying modulators of il-24 mediated apoptosis and immunotherapy


A method for identifying modulators of interleukin 24 (il-24) mediated apoptosis is disclosed. For il-24 apoptosis to be effective, the cells should express sigma 1 receptor (s1r).
Research Foundation Of The City University Of New York


03/05/15
20150064219 

Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells


Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a nlr ligand and/or tlr ligand-taa fusion protein or with an activated dc which has internalized a tumor cell which expresses an nlr- and/or tlr ligand-taa fusion protein.. .
Icahn School Of Medicine At Mount Sinai


03/05/15
20150064210 

Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome


Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (casai) using predetermined biomarkers.. .
Dendreon Corporation


03/05/15
20150064204 

Gitr antigen binding proteins


Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.


03/05/15
20150064136 

Predictors of patient response to interferon-a therapy


The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (ifn) therapy is mediated in part by inhibition of activation of mdsc and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ros) production by mdsc (as a measure of their activation) after ifn therapy is predictive of overall response to immunotherapy in cancer patients..
The University Of Pittsburgh - Of The Commonwealth System Of Higher Education


02/26/15
20150056252 

Composition and diagnosis and immunotherapy of lung cancer


The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System


02/26/15
20150056226 

Immunotherapeutic agent


The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an il-2 gene or a water-soluble tgf-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy..
Catholic University Industry Academic Cooperation Foundation


02/19/15
20150050301 

Contiguous overlapping peptides for treatment of house dust mites allergy


Contiguous overlapping peptides (cops) for the treatment of allergic patients by specific immunotherapy (sit) are provided from the sequence of the major allergens of house dust mites der p 1 and der p 2. Such peptides while providing all potential t cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind ige.
Anergis S.a.


02/19/15
20150050299 

Methods for enhancing immune response


This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (pbt) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction.
Lankenau Institute For Medical Research


02/12/15
20150044240 

P53 vaccines for the treatment of cancers


The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells.
University Of South Florida


02/12/15
20150044224 

Materials and methods for differential treatment of cancer


The present invention concerns differential therapeutic treatment of cancer patients based on prognostic antigen/antibody profiles used for predicting (prognosticating) a clinical response (efficacy) and/or adverse event to an immunotherapy for treatment of a malignancy in a subject, and for treating or delaying the onset or relapse of a malignancy in a subject.. .
Serametrix Corporation


02/12/15
20150044165 

Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target


The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research




Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9397

5090

459671 - 0 - 102